» Articles » PMID: 8943756

Role of Non-transferrin Bound Iron in Iron Overload and Liver Dysfunction in Long Term Survivors of Acute Leukaemia and Bone Marrow Transplantation

Overview
Journal J Clin Pathol
Specialty Pathology
Date 1996 Oct 1
PMID 8943756
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To determine whether nontransferrin bound iron is present in the serum of long term survivors of acute leukaemia and bone marrow transplantation who have liver dysfunction as indicated by consistently raised serum aspartate aminotransferase (AST) activities.

Methods: Thirty eight patients, who were at least three years from the end of treatment, were studied. Serum samples were analysed for hepatitis C, hepatitis B, AST, ferritin, and non-transferrin bound iron. A bleomycin based assay was used to detect non-transferrin bound iron. Patient and blood bank records were examined to determine the number of units of transfused blood received by each patient.

Results: Ten patients had consistently raised serum AST activities. Of these, two had evidence of hepatitis C infection, one had chronic hepatitis B infection and one had chronic graft versus host disease affecting the liver. None of these four patients had detectable non-transferrin bound iron. The remaining six patients had no obvious reason for raised AST activities, but four had non-transferrin bound iron detectable in their serum as compared with only two out of 28 patients with normal AST activities. Patients with abnormal AST activities had higher serum ferritin concentrations than those with normal AST, though serum ferritin was raised in 21 of 28 patients without liver dysfunction.

Conclusion: Non-transferrin bound iron may be found in this group of patients, suggesting that iron overload is the cause of the observed liver dysfunction. Non-transferrin bound iron may also be a more specific indicator of iron overload than the serum ferritin concentrations.

Citing Articles

Iron Chelator Induces Apoptosis in Osteosarcoma Cells by Disrupting Intracellular Iron Homeostasis and Activating the MAPK Pathway.

Xue Y, Zhang G, Zhou S, Wang S, Lv H, Zhou L Int J Mol Sci. 2021; 22(13).

PMID: 34281233 PMC: 8268062. DOI: 10.3390/ijms22137168.


Iron Promotes Dihydroartemisinin Cytotoxicity ROS Production and Blockade of Autophagic Flux Lysosomal Damage in Osteosarcoma.

Shen Y, Zhang B, Su Y, Badshah S, Wang X, Li X Front Pharmacol. 2020; 11:444.

PMID: 32431605 PMC: 7214747. DOI: 10.3389/fphar.2020.00444.


Hepatic late adverse effects after antineoplastic treatment for childhood cancer.

Mulder R, Bresters D, van den Hof M, Koot B, Castellino S, Loke Y Cochrane Database Syst Rev. 2019; 4:CD008205.

PMID: 30985922 PMC: 6463806. DOI: 10.1002/14651858.CD008205.pub3.


Hepatic late adverse effects after antineoplastic treatment for childhood cancer.

Mulder R, van Dalen E, van den Hof M, Bresters D, Koot B, Castellino S Cochrane Database Syst Rev. 2011; (7):CD008205.

PMID: 21735424 PMC: 6464972. DOI: 10.1002/14651858.CD008205.pub2.

References
1.
Blum R, Carter S, Agre K . A clinical review of bleomycin--a new antineoplastic agent. Cancer. 1973; 31(4):903-14. DOI: 10.1002/1097-0142(197304)31:4<903::aid-cncr2820310422>3.0.co;2-n. View

2.
McKay P, Murphy J, Cameron S, Burnett A, Campbell M, Tansey P . Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant. 1996; 17(1):63-6. View

3.
Worwood M, Dawkins S, Wagstaff M, Jacobs A . The purification and properties of ferritin from human serum. Biochem J. 1976; 157(1):97-103. PMC: 1163820. DOI: 10.1042/bj1570097. View

4.
Von Hoff D, Rozencweig M, Layard M, Slavik M, Muggia F . Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med. 1977; 62(2):200-8. DOI: 10.1016/0002-9343(77)90315-1. View

5.
Armitage J, Burns C, Kent T . Liver disease complicating the management of acute leukemia during remission. Cancer. 1978; 41(2):737-42. DOI: 10.1002/1097-0142(197802)41:2<737::aid-cncr2820410246>3.0.co;2-7. View